New Guidelines Enhance Tardive Dyskinesia Management in Long-term Care by Neurocrine Biosciences
- Neurocrine Biosciences introduces expert consensus recommendations for improved tardive dyskinesia management in long-term care settings.
- Dr. Sanjay Keswani emphasizes the need for proactive recognition of TD symptoms among older adults in care facilities.
- Findings from KINECT-PRO study highlight significant improvements in TD symptoms in older patients treated with INGREZZA®.
New Guidelines Aim to Improve Management of Tardive Dyskinesia in Long-term Care Settings
Neurocrine Biosciences, Inc. unveils a pivotal initiative at the PALTmed PALTC26 Annual Conference, offering a set of expert consensus recommendations designed to improve the screening, diagnosis, and treatment of tardive dyskinesia (TD) in older adults residing in long-term care facilities. This initiative emerges from the collaborative work of a multidisciplinary Delphi panel, which highlights a critical need to address the significant complications surrounding the recognition and management of TD, particularly in this vulnerable population. Many older adults suffer from TD, often exacerbated by prolonged exposure to dopamine receptor blocking agents, advanced age, and the complexities of polypharmacy.
Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, stresses the importance of these recommendations, particularly since residents in long-term care settings may not consistently disclose their symptoms. This situation poses a challenge for healthcare providers attempting to manage this condition effectively. The consensus guidelines aim to arm clinicians with practical strategies, enabling them to recognize and respond to TD symptoms proactively. The intent is not only to enhance clinical decision-making but also to ultimately improve the quality of life for residents facing the dual challenges of complex medical and psychiatric conditions.
Further supporting this initiative, Neurocrine Biosciences presents compelling findings from a post-hoc analysis of the KINECT-PRO™ study, which reveal that older adults aged 65 and over can experience significant improvements in self-reported TD symptoms when treated with INGREZZA® (valbenazine) capsules. These results bolster the case for the efficacy and tolerability of INGREZZA in the older patient demographic, reinforcing the need for streamlined care pathways for this population. The combination of the new structured recommendations along with the evidence from KINECT-PRO stands to reshape treatment strategies for TD in long-term care, fostering better healthcare outcomes and significantly enhancing the lives of affected individuals.
In related news, Neurocrine Biosciences continues to prioritize research and development aimed at addressing conditions prevalent in complex patient populations. The company’s commitment to innovation not only encapsulates effective treatment solutions but also reflects a deeper understanding of the multifaceted healthcare needs of older adults, marking a significant step forward in enhancing psychiatric care across long-term care environments.